Defining and evaluating overdiagnosis

Journal of Medical Ethics

Volumn 42, Issue 11, 2016, Pages 715-716

  Hofmann, Bjørn ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84983489113     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2016-103716     Document Type: Note

References (14)

1. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 2014;370:1965-7.
2. Hofmann BM. Technological Invention of Disease. Encyclopedia of Creativity, Invention, Innovation and Entrepreneurship 2013:1786-96.
3. Christakis N. Death foretold: prophecy and prognosis in medical care. Chicago: University of Chicago Press, 1999.
4. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, et al. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 2011;33:111-21.
5. Broeders M, Paci E. The balance sheet of benefits and harms of breast cancer population-based screening in Europe: outcome research, practice and future challenges. Womens Health (Lond) 2015;11:883-90.
6. Jorgensen KJ. Mammography screening. Benefits, harms, and informed choice. Dan Med J 2013;60: B4614.
7. Paci E. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen 2012; 19(Suppl 1):5-13.
8. Paci E, Broeders M, Hofvind S, et al. European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomarkers Prev 2014;23:1159-63.
9. Screening IUPoBC. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778-86.
10. Welch HG, Passow HJ. Quantifying the benefits and harms of screening mammography. JAMA Intern Med 2014;174:448-54.
11. Hofmann B. Diagnosing overdiagnosis: conceptual challenges and suggested solutions. Eur J Epidemiol 2014;29:599-604.
12. O'Connor AM, Wennberg JE, Legare F, et al. Toward the 'tipping point': decision aids and informed patient choice. Health Affairs 2007;26:716-25.
13. Aronowitz RA. When do symptoms become a disease? Ann Intern Med 2001;134(Pt 2):803-8.
14. Gradmann C. Re-inventing infectious disease: antibiotic resistance and drug development at the Bayer Company 1945-80. Med Hist 2016;60:155-80.